



ORDER: | 23MAY2024

| DOB:

Height: 6' 2"
Weight: 200 lbs.

LAB RESULTS (RECEIVED 04JUN2024)

HivConfirmatoryPanel:	Test-not-required
Hiv:	Non-reactive
Creatinine:	0.74 (Ref. Value: 0.3 - 1.7)
HepatitisB:	Non-reactive
ChlamydiaRectal:	Not-detected
GonorrheaRectal:	Detected
ChlamydiaOral:	Detected
GonorrheaOral:	Detected
ChlamydiaGenital:	Not-detected
GonorrheaGenital:	Detected

PATIENT CONSULT COMPLETED: 28MAY2024, 7:12 PM

SOAP NOTES

- 4JUN24 | 3:25PM

Patient is a good candidate for PrEP, and had no concerns. Notified of STI result and need for treatment. Will transmit Rx now.

- 28MAY24 | 8:06PM

Patient is a good candidate for PrEP, and had no concerns. Will transmit Rx for Descovy when labs are in.

PRESCRIPTION DETAILS

Prescription for Descovy, 200-25mg oral tablet with 2 re-fills sent by at 3:25PM, 04JUN2024.
Diagnosis code: ICD-10: Z20.6

Following CDC guidelines and taking into consideration the patient's medical history, my consultation with patient and their risk for HIV infection I am recommending that this patient start Descovy for pre-exposure prophylaxis (PrEP).

TeleDocs

1521 ALTON RD, SUITE 463
MIAMI BEACH, FL 33139
P: 747.999.6249 | F: 786.513.6480 | E: PA@MISTR.COM

To Whom it May Concern:

As you are aware, both Descovy (emtricitabine/tenofovir alafenamide) and Truvada (emtricitabine/tenofovir disoproxil fumarate) are two antiretroviral agents that are commonly prescribed. For many years, Truvada was the only FDA-approved drug for pre-exposure prophylaxis (PrEP) for the prevention of HIV. However, in October 2019, Descovy also received FDA approval for PrEP (although not for cisgender women or injection-drug users). Since that time, many patients' PrEP regimen was changed from Truvada to Descovy.

Although both drugs are effective in preventing HIV infection, the DISCOVER trial clearly showed that TAF is non-inferior to TDF with significant improvement in both kidney function and bone mineral density. In addition, this same trial showed the incidence of adverse events in general to be lower in the TAF group compared to the TDF group. Based on this information, we believe that Descovy is the best option for our patient.

We are asking that you consider the approving Descovy for the prevention of HIV in this patient.

Thank you for your consideration in this matter.

Respectfully,



Dr. Andrew Dattila
NPI: 1902076821

6/17/2024

Date

References

Ruane P et al. *Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis: week 96 results*. 17th European AIDS Conference, Basel, poster presentation PE3.16, 2019.